ATE288759T1 - Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln - Google Patents
Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimittelnInfo
- Publication number
- ATE288759T1 ATE288759T1 AT00910993T AT00910993T ATE288759T1 AT E288759 T1 ATE288759 T1 AT E288759T1 AT 00910993 T AT00910993 T AT 00910993T AT 00910993 T AT00910993 T AT 00910993T AT E288759 T1 ATE288759 T1 AT E288759T1
- Authority
- AT
- Austria
- Prior art keywords
- producing anti
- stabilized oligonucleotides
- tumoral drugs
- tumoral
- drugs
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9903433A FR2790955B1 (fr) | 1999-03-19 | 1999-03-19 | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| PCT/FR2000/000676 WO2000056342A2 (fr) | 1999-03-19 | 2000-03-17 | Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE288759T1 true ATE288759T1 (de) | 2005-02-15 |
Family
ID=9543401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00910993T ATE288759T1 (de) | 1999-03-19 | 2000-03-17 | Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7700569B1 (enExample) |
| EP (1) | EP1162982B9 (enExample) |
| JP (1) | JP2002539265A (enExample) |
| AT (1) | ATE288759T1 (enExample) |
| AU (1) | AU3300600A (enExample) |
| CA (1) | CA2371990A1 (enExample) |
| DE (1) | DE60018050T2 (enExample) |
| DK (1) | DK1162982T3 (enExample) |
| ES (1) | ES2235839T3 (enExample) |
| FR (1) | FR2790955B1 (enExample) |
| PT (1) | PT1162982E (enExample) |
| WO (1) | WO2000056342A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2711670B1 (fr) * | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| DK1077722T3 (da) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| DE60044236D1 (de) | 1999-02-17 | 2010-06-02 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| EA007232B1 (ru) | 2001-08-17 | 2006-08-25 | Коли Фармасьютикал Гмбх | Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| NZ540098A (en) | 2002-10-29 | 2008-09-26 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
| CA2542099A1 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| EP1649859A1 (fr) * | 2004-10-22 | 2006-04-26 | Institut Gustave Roussy | Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide |
| WO2006010838A2 (fr) * | 2004-06-25 | 2006-02-02 | Institut Gustave Roussy | Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| KR20070110901A (ko) | 2005-03-04 | 2007-11-20 | 다이나박스 테크놀로지 코퍼레이션 | 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신 |
| JP5646320B2 (ja) | 2007-05-11 | 2014-12-24 | アダイニクス， インコーポレイテッド | 遺伝子発現と疼痛 |
| FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| US20130210896A1 (en) * | 2011-11-09 | 2013-08-15 | City Of Hope | Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System |
| RU2668136C2 (ru) | 2012-05-10 | 2018-09-26 | Эйдинкс, Инк. | Композиции для доставки активных ингредиентов |
| CN106661578B (zh) | 2014-08-15 | 2020-08-04 | 埃迪恩克斯股份有限公司 | 用于疼痛治疗的寡核苷酸诱饵 |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| CA3093093A1 (en) | 2018-03-07 | 2019-09-12 | Transgene | Parapoxvirus vectors |
| CA3124773A1 (en) | 2018-12-28 | 2020-07-02 | Transgene | M2-defective poxvirus |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734033A (en) * | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| JPH04352724A (ja) * | 1990-07-27 | 1992-12-07 | Mitsui Toatsu Chem Inc | 免疫調節型治療剤 |
| EP0468520A3 (en) * | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| AU2580892A (en) | 1991-09-05 | 1993-04-05 | Isis Pharmaceuticals, Inc. | Determination of oligonucleotides for therapeutics, diagnostics and research reagents |
| DE69429617T2 (de) * | 1993-04-30 | 2002-08-22 | Biognostik Gesellschaft Fuer Biomolekulare Diagnostik Mbh | Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) |
| EP0708829B8 (en) * | 1993-07-10 | 2004-07-21 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms |
| US6001982A (en) | 1993-07-29 | 1999-12-14 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| CA2172153C (en) * | 1993-09-20 | 2010-03-09 | John C. Reed | Regulation of bcl-2 gene expression |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AU713040B2 (en) * | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
| US6280978B1 (en) * | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| EP0914324B1 (en) * | 1996-05-22 | 2001-12-05 | McGILL UNIVERSITY | Specific inhibitors of dna methyltransferase enzyme |
| EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| US5965420A (en) * | 1997-03-05 | 1999-10-12 | Smithkline Beecham Corporation | Human protein kinases hYAK3 |
| WO1998055609A1 (en) * | 1997-06-06 | 1998-12-10 | The Regents Of The University Of California | Inhibitors of dna immunostimulatory sequence activity |
| DE69829984D1 (de) * | 1997-08-29 | 2005-06-02 | Univ California | Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung |
| PT1009413E (pt) * | 1997-09-05 | 2007-05-31 | Univ California | Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma. |
| US5874416A (en) * | 1997-11-07 | 1999-02-23 | Sheikhnejad; Gholamreza | RAS antisense inhibition |
| US6060310A (en) | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
| US6020475A (en) | 1998-02-10 | 2000-02-01 | Isis Pharmeuticals, Inc. | Process for the synthesis of oligomeric compounds |
| US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US6166239A (en) | 1998-09-04 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide protecting groups |
| JP2003524602A (ja) | 1998-09-18 | 2003-08-19 | ダイナバックス テクノロジーズ コーポレイション | ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物 |
| US6069243A (en) | 1998-10-06 | 2000-05-30 | Isis Pharmaceuticals, Inc. | Process for oligonucleotide synthesis |
| CA2344558A1 (en) | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
| US6169177B1 (en) | 1998-11-06 | 2001-01-02 | Isis Pharmaceuticals, Inc. | Processes for the synthesis of oligomeric compounds |
| US6121437A (en) | 1999-03-16 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Phosphate and thiophosphate protecting groups |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| KR20020006037A (ko) | 1999-04-19 | 2002-01-18 | 스티븐 아이. 밀러 | 세리아 및 백금족 금속을 포함하는 촉매 조성물 |
| AU780724B2 (en) * | 2000-01-14 | 2005-04-14 | Migenix Inc. | Derivatives of polyene macrolides and preparation and use thereof |
-
1999
- 1999-03-19 FR FR9903433A patent/FR2790955B1/fr not_active Expired - Fee Related
-
2000
- 2000-03-17 DE DE60018050T patent/DE60018050T2/de not_active Expired - Lifetime
- 2000-03-17 AT AT00910993T patent/ATE288759T1/de active
- 2000-03-17 WO PCT/FR2000/000676 patent/WO2000056342A2/fr not_active Ceased
- 2000-03-17 EP EP00910993A patent/EP1162982B9/fr not_active Expired - Lifetime
- 2000-03-17 US US09/937,057 patent/US7700569B1/en not_active Expired - Fee Related
- 2000-03-17 JP JP2000606246A patent/JP2002539265A/ja active Pending
- 2000-03-17 ES ES00910993T patent/ES2235839T3/es not_active Expired - Lifetime
- 2000-03-17 DK DK00910993T patent/DK1162982T3/da active
- 2000-03-17 AU AU33006/00A patent/AU3300600A/en not_active Abandoned
- 2000-03-17 PT PT00910993T patent/PT1162982E/pt unknown
- 2000-03-17 CA CA002371990A patent/CA2371990A1/fr not_active Abandoned
-
2001
- 2001-09-28 US US09/967,881 patent/US7108844B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000056342A3 (fr) | 2001-07-26 |
| EP1162982B1 (fr) | 2005-02-09 |
| EP1162982A2 (fr) | 2001-12-19 |
| DK1162982T3 (da) | 2005-06-13 |
| ES2235839T3 (es) | 2005-07-16 |
| PT1162982E (pt) | 2005-05-31 |
| WO2000056342A2 (fr) | 2000-09-28 |
| JP2002539265A (ja) | 2002-11-19 |
| DE60018050D1 (de) | 2005-03-17 |
| US7700569B1 (en) | 2010-04-20 |
| CA2371990A1 (fr) | 2000-09-28 |
| AU3300600A (en) | 2000-10-09 |
| US20020192184A1 (en) | 2002-12-19 |
| DE60018050T2 (de) | 2006-02-23 |
| FR2790955B1 (fr) | 2003-01-17 |
| FR2790955A1 (fr) | 2000-09-22 |
| EP1162982B9 (fr) | 2005-07-06 |
| US7108844B2 (en) | 2006-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60018050D1 (de) | VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn | |
| CY1111504T1 (el) | Αζαδικυκλοαλκανια ως ρυθμιστες του ccr5 | |
| CY1108279T1 (el) | 17α-ΑΛΚΥΛΟ-17β-ΟΞΥ-ΟΙΣΤΡΑΤΡΙΕΝΙΑ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ ΑΥΤΩΝ, Η ΧΡΗΣΗ ΤΩΝ 17α-ΑΛΚΥΛΟ-17β-ΟΞΥ-ΟΙΣΤΡΑΤΡΙΕΝΙΩΝ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΜΕΣΩΝ ΚΑΘΩΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΑ ΠΑΡΑΣΚΕΥΑΣΜΑΤΑ | |
| DE60103453D1 (de) | Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel | |
| TR200001892T2 (tr) | Monomer cinsi ensülin analogları ve bunların kullanımı. | |
| DE3883985D1 (de) | Ärztliches instrument und dessen herstellung. | |
| UY27455A1 (es) | Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. | |
| EP1445253A4 (en) | 4,4-DIFLUOR-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVES AND THEIR SALTS | |
| ATE84721T1 (de) | Physiologisch wirksame produkte, verfahren zur herstellung und zusammensetzung. | |
| ES2080549T3 (es) | Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo. | |
| ES2056180T3 (es) | Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina. | |
| ATE231849T1 (de) | Cyclopentabenzofuran-derivate und ihre verwendung | |
| DE69841267D1 (de) | Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit | |
| DE60015560D1 (de) | Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz | |
| HUP9904294A2 (hu) | Topiramát származékok alkalmazása neuropátiás fájdalom kezelésére alkalmas gyógyszer előállítására | |
| BR9812443A (pt) | 1-2-3-4-5-6-hexahidro-2,6-metano-3-benzazocin-10-óis substituìdos, processos para sua preparação e seu emprego como medicamentos | |
| CY1106964T1 (el) | Φαρμακα που περιεχουν ν,ν’-διυποκατεστημενες ενωσεις πιπεραζινης και η χρησιμοποιηση τους | |
| BR0211223A (pt) | Derivados de 4-aminociclohexanol substituìdos | |
| PE20030236A1 (es) | Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados | |
| BR0008681A (pt) | Derivados de 3-amino -3-arilpropan-1-ol, processo para sua obtenção, medicamento e seu uso | |
| RU95114858A (ru) | Новый пептидный фрагмент, обладающий биологической активностью инсулина | |
| MXPA02002486A (es) | Uso de dexrazoxano para tratar la psoriasis. | |
| NO20032799D0 (no) | Nye terapeutiske anvendelser av tienylsykloheksylamin- derivater | |
| TH54252A3 (th) | อนุพันธ์ไพราโซล ที่ถูกเข้าแทนที่ตัวใหม่ | |
| ES2163966A1 (es) | Glicoconjugados constituidos por la asociacion no covalente de polisacaridos con polipetidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1162982 Country of ref document: EP |